<DOC>
	<DOCNO>NCT01444859</DOCNO>
	<brief_summary>Clinical trial compare safety effectiveness 10-week supplementation Trenev Trio®/Healthy Trinity® vs. placebo otherwise healthy subject recurrent gastrointestinal symptom .</brief_summary>
	<brief_title>Trenev Trio®/Healthy Trinity® Recurrent Gastrointestinal Symptoms</brief_title>
	<detailed_description>This study double-blind , randomize , placebo-controlled , parallel group trial compare safety effectiveness supplementation Trenev Trio®/Healthy Trinity® vs. placebo otherwise healthy subject recurrent gastrointestinal symptom . Subjects recruit , follow successful completion 2-week run-in period , randomize Trenev Trio®/Healthy Trinity® placebo consume assign study product daily 10 week . The study endpoints trial include relief overall gastrointestinal symptom , acid indigestion , abdominal cramping , constipation , diarrhea , gas , bloat well product safety 10-week supplementation period .</detailed_description>
	<mesh_term>Gastrointestinal Diseases</mesh_term>
	<mesh_term>Signs Symptoms , Digestive</mesh_term>
	<criteria>1 . Age ≥18 year 2 . Body mass index 18.5 39.9 kg/m2 3 . At least three symptom rat 4 6 severity ( moderate severe discomfort ) 1 7 scale , one must acid indigestion determine `` Reflux Syndrome '' score 4 . Selfreported `` acid indigestion '' symptom ( include pain/discomfort beneath breastbone , bitter fluid mouth , bloating/nausea eat ) least 3 time per week previous 4 week 5 . Agree use contraception throughout study period , unless postmenopausal surgically sterile ( female ) 6 . Able understand voluntarily consent study understand 's nature purpose include potential risk , side effect 1 . Any GSRS symptom rat 7 severity ( severe discomfort ) 1 7 scale 2 . Diagnosed gastrointestinal disease/complication functional bowel disorder ( e.g . IBS , functional constipation , IBD , ulcer , etc . ) base physical examination document medical history , investigator 's opinion , may affect subject safety confound evaluation study endpoints 3 . Any nongastrointestinal disease/complication , investigator 's opinion , may affect subject safety confound evaluation study endpoints 4 . Regular ( &gt; 3 day per week ) prescription medication use gastrointestinal disease/condition 5 . Recent ( &lt; 6 month ) abdominal surgery reason 6 . Immunodeficiency 7 . Recent change antipsychotic medication within previous 3 month 8 . Systemic steroid use within prior month , exclude regular use asthma medication 9 . Pregnant female breastfeed 10 . Eating disorder 11 . Recent ( within 2 week ) antibiotic administration 12 . History alcohol , drug , medication abuse 13 . Daily consumption probiotic , ferment milk , and/or yogurt 14 . Known allergy substance study product 15 . Participation another study investigational product within 30 day screen</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2011</verification_date>
</DOC>